oxk3rw4

Property	Value
?:abstract	BackgroundSARS-CoV-2/COVID-19, which emerged in China in late 2019, rapidly spread across the world causing several million victims in 213 countries. Switzerland was severely hit by the virus, with 43000 confirmed cases as of September 1st, 2020. AimIn cooperation with the Federal Office of Public Health, we set up a surveillance database in February 2020 to monitor hospitalised patients with COVID-19 in addition to their mandatory reporting system. MethodsPatients hospitalised for more than 24 hours with a positive PCR test, from 20 Swiss hospitals, are included. Data collection follows a custom Case Report Form based on WHO recommendations and adapted to local needs. Nosocomial infections were defined as infections for which the onset of symptoms started more than 5 days after the patients admission date. ResultsAs of September 1st, 2020, 3645 patients were included. Most patients were male (2168 - 59.5%),and aged between 50 and 89 years (2778 - 76.2%), with a median age of 68 (IQR 54-79). Community infections dominated with 3249 (89.0%) reports. Comorbidities were frequently reported: hypertension (1481 - 61.7%), cardiovascular diseases (948 - 39.5%), and diabetes (660 - 27.5%) being the most frequent in adults; respiratory diseases and asthma (4 -21.1%), haematological and oncological diseases (3 - 15.8%) being the most frequent in children. Complications occurred in 2679 (73.4%) episodes, mostly for respiratory diseases (2470 - 93.2% in adults, 16 - 55.2% in children), renal (681 - 25.7%) and cardiac (631 - 23.8%) complication for adults. The second and third most frequent complications in children affected the digestive system and the liver (7 - 24.1%). A targeted treatment was given in 1299 (35.6%) episodes, mostly with hydroxychloroquine (989 - 76.1%). Intensive care units stays were reported in 578 (15.8%) episodes. 527 (14.5%) deaths were registered, all among adults. ConclusionThe surveillance system has been successfully initiated and provides a very representative set of data for Switzerland. We therefore consider it to be a valuable addition to the existing mandatory reporting, providing more precise information on the epidemiology, risk factors, and clinical course of these cases.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C0009566> <https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C0042776> <https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C1882062> <https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C3714514> <https://research.tib.eu/covid-19/entity/5oxk3rw4_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Thiabaud%2C_Amaury%3B_Iten%2C_Anne%3B_Balmelli%2C_Carlo%3B_Senn%2C_Laurence%3B_Troillet%2C_Nicolas%3B_Widmer%2C_Andreas%3B_Flury%2C_Domenica%3B_Schreiber%2C_Peter_W.%3B_V%C3%83%C2%A1zquez%2C_Miriam%3B_Damonti%2C_Lauro%3B_Buettcher%2C_Michael%3B_Vuichard-Gysin%2C_Danielle%3B_Kuhm%2C_Christoph%3B_Cusini%2C_Alexia%3B_Riedel%2C_Thomas%3B_Nussbaumer%2C_Yvonne%3B_Gaudenz%2C_Roman%3B_Heininger%2C_Ulrich%3B_Berger%2C_Christoph%3B_Zucol%2C_Franziska%3B_Bernhard-Stirnemann%2C_Sara%3B_Corti%2C_Natascia%3B_Zimmermann%2C_Petra%3B_Uka%2C_Anita%3B_Niederer-Loher%2C_Anita%3B_Gardiol%2C_C%C3%83%C2%A9line%3B_Roelens%2C_Maroussia%3B_Keiser%2C_Olivia>
?:doi	<https://research.tib.eu/covid-19/entity/10.1101/2020.12.10.20246884>
?:doi	10.1101/2020.12.10.20246884
?:license	cc-by-nc-nd
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	MedRxiv; WHO
?:title	SARS-CoV-2/COVID-19 hospitalised patients in Switzerland: a prospective cohort profile
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#20246884
?:year	2020

Property

Value

?:abstract

BackgroundSARS-CoV-2/COVID-19, which emerged in China in late 2019, rapidly spread across the world causing several million victims in 213 countries. Switzerland was severely hit by the virus, with 43000 confirmed cases as of September 1st, 2020. AimIn cooperation with the Federal Office of Public Health, we set up a surveillance database in February 2020 to monitor hospitalised patients with COVID-19 in addition to their mandatory reporting system. MethodsPatients hospitalised for more than 24 hours with a positive PCR test, from 20 Swiss hospitals, are included. Data collection follows a custom Case Report Form based on WHO recommendations and adapted to local needs. Nosocomial infections were defined as infections for which the onset of symptoms started more than 5 days after the patients admission date. ResultsAs of September 1st, 2020, 3645 patients were included. Most patients were male (2168 - 59.5%),and aged between 50 and 89 years (2778 - 76.2%), with a median age of 68 (IQR 54-79). Community infections dominated with 3249 (89.0%) reports. Comorbidities were frequently reported: hypertension (1481 - 61.7%), cardiovascular diseases (948 - 39.5%), and diabetes (660 - 27.5%) being the most frequent in adults; respiratory diseases and asthma (4 -21.1%), haematological and oncological diseases (3 - 15.8%) being the most frequent in children. Complications occurred in 2679 (73.4%) episodes, mostly for respiratory diseases (2470 - 93.2% in adults, 16 - 55.2% in children), renal (681 - 25.7%) and cardiac (631 - 23.8%) complication for adults. The second and third most frequent complications in children affected the digestive system and the liver (7 - 24.1%). A targeted treatment was given in 1299 (35.6%) episodes, mostly with hydroxychloroquine (989 - 76.1%). Intensive care units stays were reported in 578 (15.8%) episodes. 527 (14.5%) deaths were registered, all among adults. ConclusionThe surveillance system has been successfully initiated and provides a very representative set of data for Switzerland. We therefore consider it to be a valuable addition to the existing mandatory reporting, providing more precise information on the epidemiology, risk factors, and clinical course of these cases.

is ?:annotates of